| scholarly article | Q13442814 |
| P50 | author | David E. Kleiner | Q41449492 |
| P2093 | author name string | K Hara | |
| X Zhao | |||
| T J Liang | |||
| J H Hoofnagle | |||
| J J Feld | |||
| M G Ghany | |||
| T Heller | |||
| Y Rotman | |||
| C Koh | |||
| V Haynes-Williams | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients | Q27489398 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for Retreatment of HCV Infection | Q29619799 | ||
| Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data | Q30892564 | ||
| Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response | Q33816657 | ||
| Ribavirin improves early responses to peginterferon through improved interferon signaling | Q33987120 | ||
| Global challenges in liver disease | Q33999114 | ||
| The burden of hepatitis C in the United States | Q34984035 | ||
| Introduction to therapy of hepatitis C. | Q34984075 | ||
| Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. | Q35596873 | ||
| Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study | Q35747990 | ||
| Non-invasive evaluation of liver fibrosis using transient elastography | Q37107626 | ||
| Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. | Q37536874 | ||
| Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q42008293 | ||
| Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients | Q42671117 | ||
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 | ||
| A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin | Q42967977 | ||
| Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C | Q42984730 | ||
| Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy | Q42985646 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. | Q42990190 | ||
| A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus | Q42993069 | ||
| Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study | Q43036320 | ||
| Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin | Q43047845 | ||
| Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis | Q45414516 | ||
| The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. | Q46161384 | ||
| Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy | Q46915103 | ||
| Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients | Q50561200 | ||
| Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis | Q50569800 | ||
| Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report | Q70313812 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| hepatitis C | Q154869 | ||
| chronic hepatitis C | Q55779873 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 887-894 | |
| P577 | publication date | 2013-03-06 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy | |
| P478 | volume | 37 |
| Q37018850 | Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States |
| Q38621703 | Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study. |
| Q50717522 | Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity |
| Q33413353 | All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. |
| Q40720905 | Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. |
| Q40635207 | Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. |
| Q34310417 | Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response |
| Q40677384 | Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection |
| Q33420784 | Factors associated with the platelet count in patients with chronic hepatitis C. |
| Q42282437 | Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor |
| Q40211125 | Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection |
| Q40878925 | Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis |
| Q40722730 | Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy |
| Q40148468 | Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy |
| Q88489544 | Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis |
| Q35942041 | Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China |
| Q28076352 | Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis |
| Q37395341 | Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? |
| Q41535486 | Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. |
| Q36009336 | Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study |
| Q36394515 | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
| Q40654311 | The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study |
| Q33944273 | Trace amounts of sporadically reappearing HCV RNA can cause infection |
| Q38405059 | Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. |
| Q40075930 | Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study |
Search more.